Skip to content

Michael Thomas Henderson, Chief Executive Officer at Apogee Therapeutics, sold APGE on Jun 10, 2026

Prices as of Sep 4 · price update delayed · Every feed →

▼ SELL$53.4K614 shares at $86.89Michael Thomas Henderson Chief Executive OfficerAPGE Apogee Therapeutics, Inc.
Watch APGE
Traded
Jun 10, 2026
Disclosed
Jun 12, 2026
Filed
2 days after the trade

Form 4s are due within two business days.

Official filing (SEC Form 4) ↗

The price around the disclosure

Michael Thomas Henderson, Chief Executive Officer at Apogee Therapeutics, sold APGE on Jun 10, 2026TRADEDDISCLOSED
APGESimilar stocks (XLV — its sector index fund), rebased to APGE's price on the disclosure day
APGE since disclosure
+52.9%
after the sale
Similar stocks (XLV) since disclosure
+11.5%
XLV — its sector index fund

Change in closing price from Jun 12, 2026 (the first trading day on or after disclosure) to Sep 4, 2026. Dividends excluded. Not a return anyone earned.

Our take

None of our tested rules fired on this trade.

Other trades in the same filing

  1. ▼ SELLMichael Thomas Henderson Chief Executive OfficerAPGE Apogee Therapeutics, Inc.$634Kdisclosed Jun 12 · filed 2 days after the trade
  2. ▼ SELLMichael Thomas Henderson Chief Executive OfficerAPGE Apogee Therapeutics, Inc.$199Kdisclosed Jun 12 · filed 2 days after the trade
  3. ▼ SELLMichael Thomas Henderson Chief Executive OfficerAPGE Apogee Therapeutics, Inc.$557Kdisclosed Jun 12 · filed 2 days after the trade
  4. ▼ SELLMichael Thomas Henderson Chief Executive OfficerAPGE Apogee Therapeutics, Inc.$134Kdisclosed Jun 12 · filed 2 days after the trade
  5. ▼ SELLMichael Thomas Henderson Chief Executive OfficerAPGE Apogee Therapeutics, Inc.$90.9Kdisclosed Jun 12 · filed 2 days after the trade

See every trade on APGE →